

Lion Biotechnologies to Present at the 28th Annual Piper Jaffray Healthcare Conference

November 23, 2016 6:49 AM ET

SAN CARLOS, CA -- (Marketwired) -- 11/23/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), today announced that its President and Chief Executive Officer, Dr. Maria Fardis, and Chief Financial Officer, Greg Schiffman, will participate in a fireside chat at the upcoming 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 2:30 p.m. E.T. in New York, NY.

A live webcast of the presentation will be available by visiting the Investors section of Lion Biotechnologies' website at <http://ir.lbio.com/>. A replay of the webcast will be archived on Lion Biotechnologies' website for 30 days following the presentation.

About Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma. TIL therapy is also being evaluated in clinical trials at the National Cancer Institute and Moffitt Cancer Center. For more information, please visit <http://www.lionbio.com>.

Investor Contact:

Sarah McCabe

Stern Investor Relations, Inc.

212-362-1200

sarah@sternir.com

Media Contact:

Alex Ferrara

inVentivHealth Public Relations

212-849-9487

Alexandra.Ferrara@inventivhealth.com

Source: Lion Biotechnologies, Inc.

Released November 23, 2016